MedTrace Logo

Research on the Role of SLC1A5 in the Development of Esophageal Cancer

NCT02633436 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 100

Last updated 2016-08-12

No results posted yet for this study

Summary

To explore the significance of Solute Carrier Family 1 Member 5 (SLC1A5) in the occurrence of esophageal cancer, by comparing the expression of SLC1A5 between esophageal cancer tissues and adjacent tissues.

Conditions

  • Esophageal Cancer
  • Amino Acid Transport Disorder

Interventions

OTHER

SLC1A5 expression

To observe the expression of SLC1A5 by immunohistochemistry and WesternBlot analysis.

Sponsors & Collaborators

  • Liuzhou Maternity and Child Healthcare Hospital

    collaborator OTHER

  • Fourth Affiliated Hospital of Guangxi Medical University

    lead OTHER

Principal Investigators

  • Xiangcheng Wei · Guangxi Medical University Institutional Review Board

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2015-12-31
Primary Completion
2018-07-31
Completion
2018-08-31

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02633436 on ClinicalTrials.gov